Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Archer-Daniels-Midland Q3 Earnings Top Estimates

Archer-Daniels-Midland Co (NYSE:ADM) reported third-quarter FY21 sales growth of 34.5% year-on-year, to $20.3 billion, beating the analyst consensus of $17.9 billion.…
byShivani Kumaresan
October 26, 2021
1 minute read
Total
0
Shares
0
0
0
0
0
0
  • Archer-Daniels-Midland Co (NYSE:ADM) reported third-quarter FY21 sales growth of 34.5% year-on-year, to $20.3 billion, beating the analyst consensus of $17.9 billion.
  • Revenues from Ag Services and Oilseeds rose 36% Y/Y, Carbohydrate Solutions increased 38.8%, and Nutrition climbed 16.9%.
  • The gross profit increased 27.3% Y/Y to $1.3 billion with a margin of 6.5%.
  • The Segment operating margin was 4.9%, and Segment operating income for the quarter rose 10.6% to $1 billion.
  • Adjusted EPS of $0.97 beat the analyst consensus of $0.89.
  • The company held $1.1 billion in cash and equivalents as of September 30, 2021.
  • Looking ahead, the company said it remains optimistic in sustainable earnings growth in the medium term.
  • Price Action: ADM shares are trading lower by 1.73% at $65.48 on the last check Tuesday.
 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

AstraZeneca Announced Enhertu Significantly Delayed Disease Progression in DESTINY-Breast02 Phase III Trial vs. Physician’s Choice of Treatment in Patients with HER2-positive Metastatic Breast Cancer

By Charles Gross
Today, 4:26 AM
Positive high-level results from the DESTINY-Breast02 Phase III trial of Enhertu (trastuzumab deruxtecan) versus physician's choice of treatment showed the trial met the primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS) in patients with HER2-positive unresectable and/or metastatic breast cancer previously treated wi

AZN